Our sister project, Amyloid imaging to prevent Alzheimer’s disease (AMYPAD), which began its activities on 1 October 2016, has recently been invited to two international conferences. Members of the project consortium gave two poster presentations, at the following events:
- The Lancet Neurology Conference “Preclinical neurodegenerative disease: towards prevention and early diagnosis”, London 19-21 October 2016.
- The Human Amyloid Imaging (HAI) 2017 conference, Miami Beach, Florida, US, 11-13 Jan 2017.
The focus of the Lancet Neurology Conference in London was prevention and early diagnosis of neurodegenerative diseases. The objectives and design of both AMYPAD and of our project EPAD were introduced to the scientific community, who welcomed with great interest and enthusiasm the efforts of identifying a trial-readiness cohort for secondary prevention of Alzheimer’s disease (AD). The need to find new and more effective ways to identify subjects at high risk of developing Alzheimer’s dementia before they actually experience the clinical symptoms was underlined throughout the talks, and the level of commitment from both projects to those objectives was demonstrated to participants at the congress.
The AMYPAD project aims to improve the diagnostic workup and management of patients suspected to have AD. The partners aim to improve knowledge of the natural history of AD in a pre-symptomatic stage, in order to better select patients for trials. In addition, they will monitor changes in beta amyloid deposition in the brain, in order to quantify the impact of novel therapies.
For more information about the project visit: www.amypad.eu
Pictured: Silvia Ingala from VUmc with the poster presentation at The Lancet Neurology Conference.
The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.